OOIR: Observatory of International Research

Papers

(The TQCC of Current Atherosclerosis Reports is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	91
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	90
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	85
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	73
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	67
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	60
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	60
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	58
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	57
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	57
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	56
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	50
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	50
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	48
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	47
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	46
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	45
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	43
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	43
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	40
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	38
The Emerging Specialty of Cardio-Rheumatology	38
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	36
Myeloid Cells in Abdominal Aortic Aneurysm	36
Inflammation in the Peri-ACS Period: Ready for Prime Time?	36

Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	35
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	34
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	32
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	32
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	32
The Role of Sleep in Cardiovascular Disease	31
Percutaneous Coronary Interventions in Women	30
Lipoprotein(a): from Causality to Treatment	30
RNA Silencing in the Management of Dyslipidemias	29
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	29
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	27
Low LDL-C: Is It all Good News?	27
Update on Plant-Based Diets and Cardiometabolic Risk	27
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	26
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	26
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease	25
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	24
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	23
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	23
Transgender Cardiovascular Health: Practical Management for the Clinician	22
Importance of Nutrition Security to CVD Prevention Efforts in the USA	22
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	22
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	21
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	21
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	20
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	20
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	20
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	19
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	19
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	19
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	19
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	18
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	18
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	18
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	17
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	17
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges	17
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	16
Clinical Management of Dyslipidemia in Infants and Toddlers	16
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	16
Gene Regulatory Networks in Coronary Artery Disease	16
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	16
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	15
Cardiovascular Health and Disease in the Pakistani American Population	15
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	15
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	15
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	15

Natural Sirtuin1 Activators and Atherosclerosis: an Overview	15
Utility of FFRCT in Patients with Chest Pain	14
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	14
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	14
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	14
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Bempedoic Acid: for Whom and When	14
What Causes Premature Coronary Artery Disease?	14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	13
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	13
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	13
Circular RNA role in Atherosclerosis Development and Progression	13
Fixed Combination for the Treatment of Dyslipidaemia	12
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	12
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	12
Apheresis: What Should a Clinician Know?	11
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	11
The TICE Pathway: Mechanisms and Potential Clinical Applications	11
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies	11
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	11
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	11
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	11
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics	11
Imaging Approaches to the Diagnosis of Vascular Diseases	11
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	11
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	11
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	11
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	11
Statins and Inflammation	11
Obicetrapib—the Rebirth of CETP Inhibitors?	11